OncoMatch/Clinical Trials/NCT07250477
Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer
Is NCT07250477 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment. and Standard of Care for non-small cell lung cancer stage iiic.
Treatment: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment. · Standard of Care — This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK sensitizing alteration
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1
Required: EGFR sensitizing alteration
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1
Required: HER2 (ERBB2) sensitizing alteration
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1
Required: MET exon 14 alteration
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1
Required: NTRK1 sensitizing alteration
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1
Required: NTRK2 sensitizing alteration
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1
Required: NTRK3 sensitizing alteration
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1
Required: RET sensitizing alteration
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1
Required: ROS1 sensitizing alteration
Tumor with known sensitizing alteration in ALK, EGFR, HER2, MET exon 14, NTRK, RET, or ROS1
Disease stage
Required: Stage IIIC, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: systemic therapy
Exception: Patients who previously completed systemic therapy for early stage or locally advanced NSCLC ≥ 80 days prior to trial registration are eligible for inclusion.
Previous systemic therapy for metastatic Stage IIIC or IV NSCLC
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of California Davis Comprehensive Cancer Center · Sacramento, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07250477 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK sensitizing alteration is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR sensitizing alteration is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 sensitizing alteration is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify